Premium
A multi‐centre study on the performance of the molecular genotyping platform ID RHD XT for resolving serological weak RhD phenotype in routine clinical practice
Author(s) -
Londero Donatella,
Monge Jorge,
Hellberg Asa
Publication year - 2020
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12886
Subject(s) - genotyping , medicine , serology , typing , genotype , rh blood group system , immunology , pediatrics , antibody , biology , genetics , gene
Background and objectives There is concern regarding the lack of prevention of unnecessary transfusion of RhD negative red cells and unnecessary administration of Rh immunoglobulin (RhIG) to pregnant women. In this study, performance of ID RHD XT, a genotyping assay for identification of six RHD allelic variants and human platelet antigens HPA‐1a/1b was assessed. Materials and methods Whole blood samples presenting weak, discrepant or inconclusive D phenotype results were genotyped with ID RHD XT and compared to reference molecular tests. Candidacy for RhIG prophylaxis was determined by analysing samples from pregnant women. Hands‐on time to complete the procedures was measured. Results Overall, 167 samples were tested (55 donors, 56 patients, 52 pregnant women and four newborns). Agreement between ID RHD XT and the reference method was 100% (51% weak D type 1, 2 or 3; 35·5% weak D Types 1, 2 or 3 not detected; 4% RHD deletion; 1% RHD*Pseudogene ; 1% RHD*DIIIa‐CE(3‐7)‐D ; and 4% no amplification variant detected for RHD genotype; and 64% HPA‐1a/a; 30% HPA‐1a/b; and 3% HPA‐1b/b for HPA‐1 genotype). Call rate was 98·2%. ID RHD XT identified 40% of the pregnant women that would not have required RhIG prophylaxis. Overall hands‐on time was 25–45 min to process a batch of 24 samples, and four hours for total assay time. Conclusion ID RHD XT yielded reproducible results for RHD typing in serologically weak D phenotype individuals. ID RHD XT was proven useful for the correct management of patients with RhD serological discrepancies and the rational use of RhIG in pregnancy.